CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 64 enrolled
Drug / intervention
AGN-199201 Formulation A +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01579084
NCT01579084Phase 1Completed
CompareCT.gov

Safety and Tolerability of AGN-199201 in Patients With Erythema Associated With Rosacea

Allergan·interventional·Posted Apr 17, 2012·Updated Nov 18, 2019

In Brief

A Phase 1 clinical trial evaluating AGN-199201 Formulation A, AGN-199201 Formulation B, and 2 other interventions for Rosacea and Erythema. Completed, enrolled 64 participants across 1 site.

Detailed Summary

This study will evaluate the safety and tolerability of AGN-199201 for the treatment of erythema associated with rosacea.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRosacea, Erythema
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedApr 17, 2012
Enrollment StartApr 1, 2012
Primary CompletionJun 1, 2012
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 14.2 years ago

Interventions

AGN-199201 Formulation Adrug

AGN-199201 Formulation A applied to the face as per protocol twice daily.

AGN-199201 Formulation Bdrug

AGN-199201 Formulation B applied to the face as per protocol twice daily.

AGN-199201 Formulation Cdrug

AGN-199201 Formulation C applied to the face as per protocol twice daily.

AGN-199201 Vehicledrug

AGN-199201 vehicle (placebo) applied to the face as per protocol twice daily.